News
John Smaug
- October 10, 2023
Renovaro Biosciences, a Los Angeles-based biotechnology firm, witnessed a rise in its shares on Tuesday following the appointment of two finance industry veterans to its board. The stock surged by 15% to $5.01 during afternoon trading, reflecting a over a quadruple increase in its value over the course of this year.
A Valuable Addition to the Board
Renovaro announced that Leni Boeren and Ruud Hendriks would be joining the board as independent directors in preparation for the proposed combination with artificial intelligence company GEDi Cube. Boeren brings with her an extensive 40-year career in the financial sector, having held positions at Paribas, Rabobank, Amsterdam Exchanges, and Euronext, in addition to serving as chief executive and chair of Robeco Groep. On the other hand, Hendriks boasts a career spanning 35 years, having worked at Goldman Sachs Asset Management and Robeco, as well as providing advisory services to private-equity firm KKR.
Expertise for Advancing Towards Commercialization
Renovaro Chairman Rene Sindlev expressed his enthusiasm for the new additions to the board, stating that their substantial experience in the capital markets and asset management will provide invaluable financial and business expertise as the company progresses towards commercialization.
Our Latest News
U.K. Stocks Experience Minor Decline
The U.K. stock market closed slightly lower, with some companies experiencing losses and others seeing gains in their share prices. The pound weakened against t...
Charles Schwab Reports Slower Asset Growth in July
Charles Schwab saw a decrease in asset growth in July due to advisors leaving TD Ameritrade. This article discusses inheritance challenges, optimal portfolio di...
Tax Season is Here: Consumers Prepare for Refunds
Explore the anticipated surge in consumer spending fueled by tax refunds during the tax season. Lower-income individuals are expected to benefit the most this y...